Navigation Links
UK Department for International Development commits £ 30 million to DNDi
Date:8/21/2013

[Geneva, Switzerland 22 August 2013] The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of 30 million ( 35 million) over the coming five years (2013-2018) to DNDi's Research & Development (R&D) portfolio to fight neglected diseases. This grant is part of DFID's larger investment of 138 million in nine product development partnerships (PPDs), including DNDi, for the development of new health tools to address poverty-related diseases.

After a first grant to DNDi from 2006-2008, followed by another from 2009-2013, DFID has played a key role in the achievements of the not-for-profit R&D organization. DNDi's R&D efforts focus on neglected diseases such as sleeping sickness (or human African trypanosomiasis), leishmaniasis, Chagas disease, specific filarial diseases (onchocerciasis, elephantiasis, Loa loa filariasis), and malaria. In its first 10 years of existence, DNDi and its partners have developed and made available six improved treatments to patients: two malaria fixed-dose combinations, one sleeping sickness combination therapy, one combination therapy for visceral leishmaniasis (VL) in East Africa, a set of treatment modalities for VL in Asia, and one paediatric dosage form for Chagas disease.

Over the next five years, DNDi and its partners will continue to develop improved treatments based on existing drugs and work to ensure access to them in order to address the most pressing needs of neglected patients. Furthermore, DNDi's portfolio includes 11 new chemical entities (NCEs) in preclinical or clinical development with the potential of becoming innovative treatments adapted to the needs of neglected patients, that is to say oral, safe, short-course, effective, field-adapted, and affordable.

'DFID's major long-term commitment to working with and supporting partnership models is key to our work and successes. This grant is a tremendous boost for the new compounds that we are bringing through the R&D pipeline. At this stage of maturity of our portfolio, solid funding and partnership count more than ever', comments Dr Bernard Pcoul, Executive Director of DNDi. 'DFID's support allows us to pursue R&D for treatments that are needed to address the reduction of the global neglected disease burden and to improve the quality of life of patients.'

As an essential part of its partnership model, DNDi reinforces research capacities in neglected disease-endemic regions via disease specific clinical research platforms. Key to the sustainable development of in-country scientific capacity, these platforms serve to define patients' needs, reinforce local expertise, conduct clinical trials, and facilitate registration and uptake of new treatments for neglected diseases. Globally, DNDi brings together a broad range and growing number of public and private partners, each contributing its particular expertise to deliver new health tools for neglected diseases.

'Working together in product development partnerships, the public and private sectors have a chance to bring together their expertise for the benefit of millions of the world's poorest and most vulnerable people', said the UK's Secretary of State for International Development, Honorable Justine Greening.


'/>"/>

Contact: Violaine Dällenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Public Health Accreditation Board Awards National Accreditation to Five High-performing Health Departments
2. Dr. Jeffrey Kenkel Appointed as Education Director of Department of Plastic Surgery at UT Southwestern Medical Center
3. BMA Management Memory Care Community Earns Deficiency-Free Survey from State Department
4. BMA Management Affordable Assisted Living Community Earns Deficiency-Free Survey From State Department
5. Sarles Rural Fire Department Receives $5,000 Donation from Bayer CropScience
6. Trial finds more support for universal HIV screening in emergency departments
7. TriCore Reference Laboratories Enlists Renodis to Provide a World-Class Telecom Department
8. Patient factors play key role in emergency department imaging
9. Kawartha Lakes Personal Trainer Donates All Proceeds from Fit Body Boot Camp Grand Opening Fundraising Event to Support Local Fire Department’s Fire Education Program
10. Extended primary care office hours might help keep kids out of the emergency department
11. Recycle Solutions Inc. to Expand Recycling Services to U.S. Government with New Certification from the Department of Veterans Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a Telly ... over four countries and millions of viewers in a partnership with the Amazon Video ... On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be going ...
(Date:8/16/2017)... ... 2017 , ... Richard Strawn’s new book Surgical Psalms ... a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, as ... shows love to those who are sick., Surgical Psalms contains 36 reflections about ...
(Date:8/16/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to Test Country, ... the United States has undergone major changes over the last decade, particularly when it ... order to get a blood test or other lab work done. Today, most tests ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... opportunity for men and women to train as hospice volunteers. Volunteers provide much ... illness. For over 30 years, the agency has trained volunteers to be vital ...
(Date:8/16/2017)... ... 2017 , ... First Choice Emergency Room , the largest network of ... the new Medical Director of its Sienna Plantation facility. , “We are pleased ... Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
Breaking Medicine Technology: